231 related articles for article (PubMed ID: 27323394)
1. Mutation spectrum of TP53 gene predicts clinicopathological features and survival of gastric cancer.
Tahara T; Shibata T; Okamoto Y; Yamazaki J; Kawamura T; Horiguchi N; Okubo M; Nakano N; Ishizuka T; Nagasaka M; Nakagawa Y; Ohmiya N
Oncotarget; 2016 Jul; 7(27):42252-60. PubMed ID: 27323394
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtyping of gastric cancer combining genetic and epigenetic anomalies provides distinct clinicopathological features and prognostic impacts.
Tahara T; Tahara S; Horiguchi N; Okubo M; Terada T; Yamada H; Yoshida D; Omori T; Osaki H; Maeda K; Kamano T; Funasaka K; Nagasaka M; Nakagawa Y; Shibata T; Ohmiya N
Hum Mutat; 2019 Mar; 40(3):347-354. PubMed ID: 30575210
[TBL] [Abstract][Full Text] [Related]
3. Analysis of full coding sequence of the TP53 gene in invasive vulvar cancers: Implications for therapy.
Kashofer K; Regauer S
Gynecol Oncol; 2017 Aug; 146(2):314-318. PubMed ID: 28527674
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection.
Shimizu T; Marusawa H; Matsumoto Y; Inuzuka T; Ikeda A; Fujii Y; Minamiguchi S; Miyamoto S; Kou T; Sakai Y; Crabtree JE; Chiba T
Gastroenterology; 2014 Aug; 147(2):407-17.e3. PubMed ID: 24786892
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
6. Initial and crucial genetic events in intestinal-type gastric intramucosal neoplasia.
Rokutan H; Abe H; Nakamura H; Ushiku T; Arakawa E; Hosoda F; Yachida S; Tsuji Y; Fujishiro M; Koike K; Totoki Y; Fukayama M; Shibata T
J Pathol; 2019 Apr; 247(4):494-504. PubMed ID: 30474112
[TBL] [Abstract][Full Text] [Related]
7. Reduced MUTYH, MTH1, and OGG1 expression and TP53 mutation in diffuse-type adenocarcinoma of gastric cardia.
Kohno Y; Yamamoto H; Hirahashi M; Kumagae Y; Nakamura M; Oki E; Oda Y
Hum Pathol; 2016 Jun; 52():145-52. PubMed ID: 26980051
[TBL] [Abstract][Full Text] [Related]
8. Systematic Inspection of the Clinical Relevance of TP53 Missense Mutations in Gastric Cancer.
Moon S; Balch C; Park S; Lee J; Sung J; Nam S
IEEE/ACM Trans Comput Biol Bioinform; 2019; 16(5):1693-1701. PubMed ID: 29994072
[TBL] [Abstract][Full Text] [Related]
9. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
10. TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome.
Migliavacca M; Ottini L; Bazan V; Agnese V; Corsale S; Macaluso M; Lupi R; Dardanoni G; Valerio MR; Pantuso G; Di Fede G; Tomasino RM; Gebbia N; Mariani-Costantini R; Russo A
J Cell Physiol; 2004 Sep; 200(3):476-85. PubMed ID: 15254976
[TBL] [Abstract][Full Text] [Related]
11. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
Pallocca M; Goeman F; De Nicola F; Melucci E; Sperati F; Terrenato I; Pizzuti L; Casini B; Gallo E; Amoreo CA; Vici P; Di Lauro L; Buglioni S; Diodoro MG; Pescarmona E; Mazzotta M; Barba M; Fanciulli M; De Maria R; Ciliberto G; Maugeri-Saccà M
J Transl Med; 2018 Sep; 16(1):247. PubMed ID: 30180862
[TBL] [Abstract][Full Text] [Related]
12. TP53 codon 72 and intron 3 polymorphisms and mutational status in gastric cancer: an association with tumor onset and prognosis.
Neves Filho EH; Cordeiro DE; Vieira AP; Rabenhorst SH
Pathobiology; 2012; 79(6):323-8. PubMed ID: 22688387
[TBL] [Abstract][Full Text] [Related]
13. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
[TBL] [Abstract][Full Text] [Related]
15. TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.
Seagle BL; Yang CP; Eng KH; Dandapani M; Odunsi-Akanji O; Goldberg GL; Odunsi K; Horwitz SB; Shahabi S
Gynecol Oncol; 2015 Jul; 138(1):159-64. PubMed ID: 25958320
[TBL] [Abstract][Full Text] [Related]
16. Identification of early genetic changes in well-differentiated intramucosal gastric carcinoma by target deep sequencing.
Yoshida T; Yamaguchi T; Maekawa S; Takano S; Kuno T; Tanaka K; Iwamoto F; Tsukui Y; Kobayashi S; Asakawa Y; Shindo H; Fukasawa M; Nakayama Y; Inoue T; Uetake T; Ohtaka M; Sato T; Mochizuki K; Enomoto N
Gastric Cancer; 2019 Jul; 22(4):742-750. PubMed ID: 30756200
[TBL] [Abstract][Full Text] [Related]
17. Role of p53 in the progression of gastric cancer.
Busuttil RA; Zapparoli GV; Haupt S; Fennell C; Wong SQ; Pang JM; Takeno EA; Mitchell C; Di Costanzo N; Fox S; Haupt Y; Dobrovic A; Boussioutas A
Oncotarget; 2014 Dec; 5(23):12016-26. PubMed ID: 25427447
[TBL] [Abstract][Full Text] [Related]
18. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
[TBL] [Abstract][Full Text] [Related]
19. Lineage analysis of early and advanced tubular adenocarcinomas of the stomach: continuous or discontinuous?
Nakayama T; Ling ZQ; Mukaisho K; Hattori T; Sugihara H
BMC Cancer; 2010 Jun; 10():311. PubMed ID: 20565940
[TBL] [Abstract][Full Text] [Related]
20. p53 immunostaining cannot be used to predict TP53 mutations in gastric cancer: results from a large Central European cohort.
Schoop I; Maleki SS; Behrens HM; Krüger S; Haag J; Röcken C
Hum Pathol; 2020 Nov; 105():53-66. PubMed ID: 32971129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
